首页> 美国卫生研究院文献>other >Encapsulation of Bacteriophage in Liposome Accentuates Its Entry in to Macrophage and Shields It from Neutralizing Antibodies
【2h】

Encapsulation of Bacteriophage in Liposome Accentuates Its Entry in to Macrophage and Shields It from Neutralizing Antibodies

机译:噬菌体在脂质体中的包封可加快其进入巨噬细胞的速度并使其免受中和抗体的侵害。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Phage therapy has been a centre of attraction for biomedical scientists to treat infections caused by drug resistant strains. However, ability of phage to act only on extracellular bacteria and probability of interference by anti-phage antibodies in vivo is considered as a important limitation of bacteriophage therapy. To overcome these hurdles, liposome were used as delivery vehicle for phage in this study. Anti-phage antibodies were raised in mice and pooled serum was evaluated for its ability to neutralize free and liposome entrapped phage. Further, ability of phage and liposome-entrapped phage to enter mouse peritoneal macrophages and kill intracellular Klebsiella pneumoniae was compared. Also, an attempt to compare the efficacy of free phage and liposome entrapped phage, alone or in conjunction with amikacin in eradicating mature biofilm was made. The entrapment of phage in liposome provided 100% protection to phage from neutralizing antibody. On the contrary un-entrapped phage got neutralized within 3 h of its interaction with antibody. Compared to the inability of free phage to enter macrophages, the liposome were able to deliver entrapped phage inside macrophages and cause 94.6% killing of intracellular K. pneumoniae. Liposome entrapped phage showed synergistic activity along with amikacin to eradicate mature biofilm of K. pneumoniae. Our study reinforces the growing interest in using phage therapy as a means of targeting multidrug resistant bacterial infections as liposome entrapment of phage makes them highly effective in vitro as well as in vivo by overcoming the majority of the hurdles related to clinical use of phage.
机译:噬菌体疗法一直是生物医学科学家治疗由耐药菌株引起的感染的吸引力中心。然而,噬菌体仅对细胞外细菌起作用的能力以及体内抗噬菌体抗体干扰的可能性被认为是噬菌体治疗的重要限制。为了克服这些障碍,在这项研究中将脂质体用作噬菌体的递送载体。在小鼠中产生抗噬菌体抗体,并评估合并的血清中和游离的和脂质体包裹的噬菌体的能力。此外,比较了噬菌体和包裹脂质体的噬菌体进入小鼠腹膜巨噬细胞并杀死细胞内肺炎克雷伯菌的能力。另外,尝试比较游离噬菌体和脂质体包裹的噬菌体单独或与丁胺卡那霉素联合用于消除成熟生物膜的功效。噬菌体在脂质体中的捕获为噬菌体提供了100%的中和抗体保护。相反,未捕获的噬菌体在与抗体相互作用的3小时内被中和。与游离噬菌体不能进入巨噬细胞相比,脂质体能够将捕获的噬菌体递送到巨噬细胞内部,并杀死94.6%的细胞内肺炎克雷伯菌。包裹脂质体的噬菌体与丁胺卡那霉素一起发挥协同作用,以根除肺炎克雷伯菌的成熟生物膜。我们的研究增强了人们对使用噬菌体疗法作为靶向多药耐药细菌感染的手段的兴趣,因为噬菌体的脂质体截留通过克服与噬菌体临床使用相关的大部分障碍,使其在体外和体内均非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号